X4 raises $27M to take Sanofi’s old drug through pivotal trial
Cambridge, MA-based startup X4 Pharmaceuticals just bagged $27 million to take its two lead drugs — one for cancer, the other for rare disease — to Phase II and III trials.
X4 has moved quickly. The company emerged in 2015 with a $37.5 million launch round and an oncology asset it had picked up from Sanofi’s toss pile. The company’s oral, small molecule drug candidates inhibit the binding of chemokine CXCL12 to CXCR4, a receptor-ligand pair that plays a role in normal immune surveillance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.